EnteroMedics (NASDAQ: RSLS) is one of 80 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its rivals? We will compare EnteroMedics to similar companies based on the strength of its analyst recommendations, dividends, valuation, risk, institutional ownership, profitability and earnings.
Volatility & Risk
EnteroMedics has a beta of 3.09, indicating that its stock price is 209% more volatile than the S&P 500. Comparatively, EnteroMedics’ rivals have a beta of 1.28, indicating that their average stock price is 28% more volatile than the S&P 500.
Earnings and Valuation
This table compares EnteroMedics and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|EnteroMedics Competitors||$2.14 billion||$229.91 million||-29.82|
EnteroMedics’ rivals have higher revenue and earnings than EnteroMedics. EnteroMedics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current recommendations and price targets for EnteroMedics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
EnteroMedics presently has a consensus price target of $11.03, suggesting a potential upside of 635.33%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 9.95%. Given EnteroMedics’ stronger consensus rating and higher possible upside, research analysts clearly believe EnteroMedics is more favorable than its rivals.
This table compares EnteroMedics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
0.6% of EnteroMedics shares are held by institutional investors. Comparatively, 50.2% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 32.5% of EnteroMedics shares are held by insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
EnteroMedics rivals beat EnteroMedics on 7 of the 12 factors compared.
ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.